Hemodialysis Procedure Does Not Affect the Levels of sICAM-1 and sVCAM-1 in Patients with End Stage Renal Disease

Figures & data

Table 1. Clinical and laboratory features of patients with end stage renal disease on hemodialysis (n = 35).

		All patients	Cuprophana-Dialyzer	Polysulfonb-Dialyzer
Patients	(n)	35	22	13
Age	(years)	61 ± 12	64 ± 10	57 ± 15
Gender	(m/f)	18/17	11/11	7/6
Body weight	(kg)	65 ± 12	64 ± 14	66 ± 6,9
Time on dialysis	(months)	39 ± 38	25 ± 24	65 ± 46
Diabetes mellitus	(n)	8	6	2
rHuEPO therapy	(n)	16	9	7
Hypertension	(n)	23	17	6
Ultrafiltration volume	(mL)	2410 ± 721	2265 ± 706	2633 ± 713
Mean BPc	(mmHg)	94 ± 11	96 ± 12	93 ± 11
Heart rate^c	(/min)	75 ± 9	74 ± 9	76 ± 9
Creatinine^c	(µmol/L)	791 ± 140	787 ± 160	797 ± 105
Urea^c	(mmol/L)	29.3 ± 7	30.7 ± 8	26.9 ± 5
Hematocrit^c	(%)	27.4 ± 3.8	27 ± 2.2	28 ± 5.7
Hemoglobin^c	(g/L)	97 ± 13	96.6 ± 8.4	98.4 ± 18.6

^aGFS 12®, Gambro, Lund, Sweden.

^bHemoflow F 60S®; Fresenius, Oberursel, Germany.

^cPredialysis values.

Table 2. The time course of plasma sVCAM-1 (pg/mL) during hemodialysis treatment in patients with end stage renal disease (n = 35).

Time after start of hemodialysis	sVCAM-1 (pg/mL) during hemodialysis
	0 h	1 h	2 h	3 h	4 h
All patients (n = 35)	1449 ± 497	1545 ± 758	1479 ± 445	1430 ± 576	1414 ± 452
Hypertensive (n = 23)	1340 ± 476	1531 ± 899	1380 ± 360	1227 ± 403	1311 ± 381
Normotensive (n = 12)	1656 ± 488	1573 ± 398	1660 ± 539	1787 ± 404	1621 ± 528
Diabetics (n = 8)	1433 ± 452	1569 ± 276	1670 ± 446	1719 ± 608	1557 ± 396
Nondiabetics (n = 27)	1456 ± 527	1530 ± 871	1404 ± 437	1348 ± 546	1366 ± 476
Low-flux dialysis (n = 22)	1516 ± 522	1607 ± 920	1498 ± 449	1367 ± 461	1411 ± 484
High-flux dialysis (n = 13)	1336 ± 446	1441 ± 359	1447 ± 454	1527 ± 728	1419 ± 415

Note: All values are corrected for hemoconcentration according to Van Beaumont's formula. When compared to each other no statistical significance was found. They are presented as mean ± SD.

Table 3. The time course of plasma sICAM-1 (pg/mL) during hemodialysis treatment in patients with end stage renal disease (n = 35).

Time after start of hemodialysis	sICAM-1 (pg/mL) during hemodialysis
	0 h	1 h	2 h	3 h	4 h
All patients (n = 35)	231 ± 58	242 ± 75	249 ± 68	241 ± 92	247 ± 97
Hypertensive (n = 23)	224 ± 49	232 ± 52	246 ± 64	231 ± 83	232 ± 78
Normotensive (n = 12)	245 ± 73	261 ± 106	256 ± 77	260 ± 107	276 ± 127
Diabetics (n = 8)	225 ± 45	254 ± 48	258 ± 31	249 ± 49	243 ± 57
Nondiabetics (n = 27)	228 ± 59	233 ± 78	243 ± 74	235 ± 101	240 ± 102
Low-flux dialysis (n = 22)	219 ± 59	232 ± 75	252 ± 66	231 ± 62	228 ± 66
High-flux dialysis (n = 13)	252 ± 53	258 ± 75	245 ± 74	257 ± 126	275 ± 130

Note: All values are corrected for hemoconcentration according to Van Beaumont's formula. When compared to each other no statistical significance was found. They are presented as mean ± SD.

Figure 1. Serum levels of sVCAM-1 measured at 30 minutes into HD before and after the passage of the dialyzer. Values are presented as mean ± SD. There was no statistically significance difference between sVCAM-1 levels before and after the passage of the dialyzer.

Figure 2. Serum levels of sICAM-1 measured at 30 minutes into HD before and after the passage of the dialyzer. Values are presented as mean ± SD. There was no statistically significance difference between sICAM-1 levels before and after the passage of the dialyzer.